Vasculitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Vasculitis – Drugs In Development, 2024 report and make more profitable business decisions.
Vasculitis is a term that refers to a group of diseases that cause inflammation of the blood vessels, affecting both arteries and veins. Vasculitis can have various causes, such as genetic factors, infections, immune system disorders, blood cancers, or reactions to certain drugs. Vasculitis can affect different parts of the body, such as the skin, muscles, joints, nerves, lungs, heart, digestive system, kidneys, and eyes. Depending on the type and severity of vasculitis, the symptoms and complications may vary. Some common signs of vasculitis are fever, weight loss, fatigue, headache, joint pain, skin rash, and bleeding under the skin. Vasculitis can be diagnosed by blood tests, imaging tests, or biopsy of the affected tissue. Treatment options depend on the type and cause of vasculitis, but usually involve medications to reduce inflammation and prevent flare-ups.
The Vasculitis drugs in development market research report provide comprehensive information on the therapeutics under development for Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vasculitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Vasculitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 30 molecules, with 29 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Vasculitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Vasculitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Vasculitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAmbulero Inc
Amgen Inc
AnGes Inc
Antidote Therapeutics Inc
Anviron Corp
Bilix Co Ltd
Biostar Stem Cell Research Institute
Biotx.ai GmbH
Celon Pharma SA
Citryll BV
Eli Lilly and Co
Fresenius Kabi SwissBioSim GmbH
General Nanotherapeutics LLC
GSK plc
Hansa Biopharma AB
Iltoo Pharma
Johnson & Johnson
JSR Life Sciences LLC
Jubilant Therapeutics Inc
Kangpu Biopharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
Lepton Pharmaceuticals Ltd
Novartis AG
Pfizer Inc
Pharmapraxis
Provid Pharmaceuticals Inc
Shanghai YaKe Biotechnology Co Ltd
Travere Therapeutics Inc
Vasogenesis Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Vasculitis reports